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Schizophrenia, 17 
fats & lab rats
Teresa du Bois
DEPARTMENT of BIOMEDICAL SCIENCE 
NEUROSCIENCE INSTITUTE of SCHIZOPHRENIA & 
ALLIED DISORDERS (NISAD)
Last year I joined a dedicated research group on a quest to discover what causes 
schizophrenia. My honours project was designed to investigate whether fats, as 
part of the structure of cell membranes, could alter neurotransmitter function in 
the brain and potentially play a role in the disease. I found that fatty acids can 
influence neurotransmitter receptor binding in the rat brain, and may play some 
role that can be related to schizophrenia. In this article I provide an introduction 
to the science of schizophrenia and discuss new techniques that are available to 
study the disorder and insights into my own research findings.











































What is schizophrenia? Schizophrenia is a mental illness that has puzzled scientists 
for many decades, and still remains largely unresolved as to its cause. It affects 
approximately one in every hundred people, and is a significant burden on health 
expenditure in Australia.1 The illness interferes with mental functioning and, in 
the long-term, may cause changes to a person's personality. The consequences 
of having schizophrenia can be massive, both on the sufferer and their family (for 
example, see the recent media attention on the Baxter detainee, Cornelia Rau). 
Symptoms include hallucinations, delusions and thought disorganisation, as well 
as impaired motivation and decreased emotional expression.
It is generally accepted that schizophrenia involves imbalances in signalling 
chemicals of the brain called neurotransmitters. Neurotransmitters are proteins 
that carry information from cell to cell, or as they are called in the brain, neuron 
to neuron. These chemicals form part of pathways that can inhibit or excite 
neural cells. An imbalance of these pathways may contribute to symptoms of 
schizophrenia by changing the amount of activity in certain brain regions, and 
even by causing ceil death, as too much excitation can result in neurotoxicity. 
Many, if not all brain regions seem to be involved in schizophrenia, which is not 
surprising given the interconnectivity between pathways and systems.
In the past few decades, the most widely studied neurochemical explanation 
of schizophrenia has been the dopamine hypothesis, which suggests that 
hyperactivity of the dopamine system is the primary pathology of the disorder. 
This was based on the fact that antipsychotic drugs, commonly used to treat 
schizophrenia, have anti-dopaminergic properties. However this hypothesis has 
failed to produce conclusive findings. For one reason, a significant proportion 
of schizophrenia patients do not respond to anti-dopamine therapy.2'3 Also, 
alterations of various brain regions in schizophrenia do not strictly involve 
dopaminergic pathways.
Other popular theories include the neurodevelopmental hypothesis, which 
proposes that schizophrenia may be the result of a chemically based injury to 
the brain either before or during the critical period of brain development - late 
adolescence in humans. This period coincides with the age that schizophrenia 
symptoms begin to appear. During this time the brain undergoes 'synaptic 
pruning', which basically means getting rid of unnecessary cell signalling pathways 
and enhancing useful ones, making the brain more efficient.
There is also emerging evidence in support of the glutamate A/-Methyl-D-aspartate
(NMDA) receptor hypofunction hypothesis. NMDA receptor antagonists such as 
phencyclidine (PCP, angel dust) and ketamine (special K) can induce the entire 
range of core schizophrenia phenomenology including disorder of attention, 
perception and abstract thinking in normal subjects, and can exacerbate 
symptoms in patients with schizophrenia,4'5 while the psychotic effects produced 
by amphetamine (dopamine transporter inhibitor) and lysergic acid (LSD) 
(serotonin agonist) do not fully represent the scope of the main symptoms of 
schizophrenia.6 Indeed, PCP-induced psychosis is diagnostically difficult to 
differentiate from schizophrenia.7 This observation has led many researchers to 
believe that glutamate NMDA receptors are the key to unravelling the pathology 
of schizophrenia.
Techniques available for examining the 
cellular basis of schizophrenia
There are several methods of examining schizophrenia at the cellular level. 
The post mortem brain of schizophrenia has been examined extensively, with 
a number of abnormalities detected in many neurotransmitter systems. To 
measure the density of neurotransmitter receptors, the procedure involves using 
thinly sliced brain tissue sections that are treated with a radioactively tagged 
drug that binds to a specific receptor, which is present in the brain sections. To 
quantify the amount of radioactivity, and therefore the receptor density, sections 
can be exposed to radioactive-sensitive film for several months, then the film is 
developed and analysed. Alternatively, sections can be quantified using Beta- 
Imager Detection.The University of Wollongong has recently installed a BioSpace 
Beta Imager Machine in the Molecular Neurobiology Laboratory, directed by 
Associate Professor Xu-Feng Fluang. The Beta Imager is unique in that it can 
immediately measure the distribution of beta particles emerging from brain 
sections and display them on screen. The image can be directly acquired and 
quantified within around four hours,8 and it is therefore much more efficient than 
film autoradiography. Furthermore, because this is a direct capture of the beta 
particle signals, it is significantly more accurate. The Beta Imager was obtained 
through funds raised by the local lllawarra community, championed by Lord Mayor 
Alex Darling of Wollongong City Council, in partnership with the Neuroscience 
Institute of Schizophrenia and Allied Disorders (NISAD). This machine is the first 
of its kind available in the southern hemisphere.
Other new techniques available include functional magnetic resonance imaging 
(fMRI), where a patient's brain activity is assessed while performing tasks that are 
known to activate certain brain regions. Recently, using this technique, a team 









































brain structural abnormalities, and core features of the disorder (www.nisad.org. 
au). DNA microarray technology is another application of advanced technology 
allowing thousands of genes to be analysed for abnormalities simultaneously, 
and has been used to identify abnormal genes in schizophrenia.9
Treatment
Symptoms of schizophrenia patients vary significantly. Typical treatment of 
this disorder involves a lifetime of large doses of antipsychotic drugs, which 
are only partially effective, expensive, and have many undesirable side effects. 
Haloperidol, a first generation 'typical'antipsychotic drug (produced in 1960) 
is effective in treating positive symptoms, but it has severe motor side effects. 
Second generation drugs such as Olanzapine and Clozapine (produced in 1990) 
are known as'atypical'antipsychotics and are effective in treating both positive 
and negative symptoms, but can cause severe obesity. A third generation 
antipsychotic drug Aripiprazole (produced in 2003) is also effective in treating 
both positive and negative symptoms, and it does not cause obesity.
My study
My honours project was designed to see whether fatty acids could alter 
neurotransmitter function in the brain, and potentially play a role in the disease. 
The study was based on three premises: First, post mortem schizophrenia brains 
show lower levels of certain omega-3 and omega-6 fatty acids in their neural 
and red blood cell membranes, as well as altered levels of markers for fatty acid 
metabolism. Second, many neurotransmitter systems are altered in schizophrenia. 
Third, omega-3 fatty acid supplementation in addition to antipsychotic medication 
has been shown by some groups to be successful in improving mental health 
in schizophrenia patients. This result seems to depend on a dose that optimises 
the omega-3 to omega-6 ratio.101 wanted to determine if there was a connection 
between these findings, that is, is there a relationship between membrane fatty 
acid status in the brain, neurotransmitter levels and brain function?
But what have fatty acids got to do with neurotransmitters? In short, all cells 
including neurons are surrounded by a membrane that functions as a filter, 
allowing only certain materials to pass in and out of the cell. The membrane 
itself is embedded with various proteins including neurotransmitter receptors. 
Membranes are comprised of phospholipids, which are made up of different 
types of fatty acids. It has been shown that rats fed a large percentage of omega- 
3 fatty acids in their diet have a higher ratio of omega-3 fatty acids in their neural 
membrane phospholipid composition. The same can be said for other fatty 
acid types like omega-6 and saturated fats. Further studies have demonstrated
that by manipulating fatty acid content in the diet and therefore in membrane 
phospholipids, the density of neurotransmitter receptors in the brain can be 
altered.
In my study, rats were fed diets high in saturated fat, omega-3 polyunsaturated 
fatty acid (PUFA), omega-6 PUFA or a control diet for 8 weeks. I examined receptor 
subtypes from the serotonin and acetylcholine muscarinic neurotransmitter 
systems, both of which have been implicated in schizophrenia in addition to the 
popular dopamine and glutamate systems. To do this I needed to do a series of 
drug-binding experiments, involving applying a radioligand, which is a radioactive 
drug that binds to a certain receptor, to brain sections from the four diet groups. 
I measured the amount of radioactivity, and therefore the receptor density, using 
both the traditional film method (Fig. 1) and Beta-lmager technology (Fig. 2).
I analysed areas throughout the whole brain, and made several interesting 
findings.11 Compared to rats on a normal laboratory diet, rats on saturated fat, 
omega-3 and omega-6 diets all showed changes in receptor density, but these 
were quite varied. The most pronounced effects were seen in the omega-6 fed 
group, which showed increased muscarinic receptor binding in several brain 
regions. The results illustrate that diet can alter the density of neurotransmitters 
in the rat brain. So does this mean that alterations in neurotransmitter receptors 
and brain function in schizophrenia are simply due to fatty acid imbalances? 
Unfortunately it is not so simple. For one reason, abnormalities in fatty acid levels 
in schizophrenia have been attributable to metabolic abnormalities, and not to 
a dietary deficiency. It should also be pointed out that abnormal fatty acid levels 
could be a consequence of changes in neurotransmitter receptor interaction and 
not vice versa. To bring an old cliche to mind, it appears to be a case of which 
came first: the chicken or the egg? So while a definitive role for fatty acids in 
schizophrenia pathology remains uncertain, studies on the influence of fatty acids 
on neurotransmitter receptors do still have potential to improve the treatment of 












































Fig. 1. Film autoradiography showing the binding pattern of muscarinic M l/ 
M4 and M2/M4 receptor subtypes in the brain of control rats. Note the similar 
distribution of muscarinic receptor subtypes at the level of A and B, while the 
distribution of receptor subtypes differs at the level of C. The maps of A to C are 
adapted from a standard rat brain atlas indicating the levels that sections were 
cut. A'-C': [3H]pirenzepine binding to muscarinic M1/M4 receptor subtypes; A"- 
C": [3H]AF-DX384 binding to muscarinic M2/M4 receptor subtypes. Abbreviations: 
Acb: nucleus accumbens; ACC: anterior cingulate cortex; Amg: amygdala; AOP: 
anterior olfactory nucleus; CA1-3: CA1-3 fields of the hippocampus; CPU: caudate 





Fig. 2. Beta-lmager detection showing the binding pattern of serotonin 5-HT2A and 
5-HT2C receptor subtypes in the brain of control rats. Note the similar distribution 
of serotonin receptor subtypes at the level of A and B, while the distribution 
of receptor subtypes differs at the level of C. The maps of A to C are adapted 
from a rat brain atlas and indicate the levels that sections were cut. A'-C: 5-HT „
2A
receptors; A"-C": 5-HT2C receptors. Abbreviations: Acb: nucleus accumbens; ACC: 
anterior cingulate cortex; Amg: amygdala; AOP: anterior olfactory nucleus; CA1 -3: 
CA1-3 fields of the hippocampus; CPU: caudate putamen; DG: dentate gyrus; DM: 
dorsomedial hypothalamus; LH: lateral hypothalamus; PfCx: prefrontal cortex;Tu: 
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